Testagen (AEDG) – 20mg | Testicular & Male Reproductive Tissue Research Compound

Testagen is a synthetic tetrapeptide bioregulator with the sequence Ala-Glu-Asp-Gly (AEDG), developed within the Khavinson Cytogen peptide series at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as the testes-targeted member of the Cytogen family, joining Cardiogen (cardiac), Cartalax (cartilage), Cortagen (CNS), Crystagen (immune/thymic), Ovagen (ovarian), and Pancragen (pancreatic) as tissue-specific short peptide bioregulators studied for their proposed gene-regulatory mechanisms rather than classical receptor-ligand binding.

Key Research Areas:

• Testicular Tissue Gene Regulation — As a Cytogen-class peptide, Testagen’s AEDG sequence is proposed to interact with nuclear DNA regulatory regions in testicular tissue, consistent with the broader Khavinson hypothesis that short peptide bioregulators act by modulating tissue-specific gene expression programs rather than through classical receptor binding.
• Reproductive Cellular Signaling Research — Research interest in Testagen centers on its potential relationship with cellular signaling and gene-expression pathways in male reproductive tissue models, an area of research shared across the Cytogen series.
• Comparative Cytogen Mechanism Research — Because Testagen shares its core AEDG sequence with Epitalon (a distinct, more extensively studied Khavinson peptide), laboratory research in this area often draws mechanistic comparisons across Cytogen-family peptides to understand how identical or near-identical core sequences may produce tissue-differentiated effects depending on cellular context and co-factors present in target tissue.

Product Specifications:

• Sequence: Ala-Glu-Asp-Gly (AEDG)
• 20mg lyophilized powder per vial
• ≥99% purity via HPLC, third-party COA available
• Store refrigerated (2–8°C) or frozen for long-term storage; protect from light and moisture